Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891818 | 0.88 | CYP1A2 (0.57) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL5840681 | 0.85 | EPHX2 (0.54) | GAACYP1A2ALOX15ALDH1A1KMT2A | |
| SCHEMBL11792895 | 0.85 | EPHX2 (0.54) | GAACYP1A2ALOX15ALDH1A1KMT2A | |
| SCHEMBL4093617 | 0.84 | CYP1A2 (0.47) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL7088568 | 0.83 | GAA (0.54) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL12999503 | 0.81 | GAA (0.47) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL1425763 | 0.81 | GAA (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL48439 | 0.81 | GAA (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL15201482 | 0.81 | GAA (0.52) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL10057015 | 0.80 | TSHR (0.55) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2025019764-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | MATTERWORKS INC (US) | 2025-01-23 | — | — | WO | claimed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | claimed |
| WO-2023077166-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC (US) | 2023-05-04 | — | — | WO | claimed |
| US-20230137741-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2023-05-04 | — | — | US | claimed |
| CN-101341129-B | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2011-12-14 | — | — | CN | claimed |
| CN-101341129-A | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | CN | claimed |
| US-20260148950-A1 | METHODS AND SYSTEMS FOR PREDICTIVE ANALYSIS BY MASS SPECTROMETRY | MATTERWORKS INC (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20250060343-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2025-02-20 | — | — | US | disclosed |
| WO-2025019764-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | MATTERWORKS INC (US) | 2025-01-23 | — | — | WO | disclosed |
| US-12146869-B2 | Methods and compositions for analyte quantification | MATTERWORKS INC (US) | 2024-11-19 | — | — | US | disclosed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023077166-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20230133615-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2023-05-04 | — | — | US | disclosed |
| US-20230137741-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2023-05-04 | — | — | US | disclosed |
| WO-2012020749-A1 | TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOUND THAT CONTAINS SAME AND EXHIBITS ANALGESIC ACTIVITY | 塩野義製薬株式会社 (JP) | 2012-02-16 | — | — | WO | disclosed |
| CN-101341129-B | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL-MYERS SQUIBB CO. (US) | 2011-12-14 | — | — | CN | disclosed |
| CN-101341129-A | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-07 | — | — | CN | disclosed |
| CN-1938029-A | Chemokine inhibiting piperazine derivatives and their use to treat multiple myeloma | UNIV PITTSBURGH (DE) | 2007-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260148950-A1 | METHODS AND SYSTEMS FOR PREDICTIVE ANALYSIS BY MASS SPECTROMETRY | SRMS, PTMS, CALCB | GAA 4857/4885MGAM 4272/4885SI 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.